Market Newsdesk

MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026.

Mr. Edwards brings more than 25 years of commercial leadership experience across immunology and dermatology, spanning both biologics and topical therapies. He joins Oruka from Arcutis Biotherapeutics, Inc., where he served as Executive Vice President and Chief Commercial Officer and led a transformation of the ZORYVE® franchise – rebuilding the PsO commercial organization, launching new indications in atopic dermatitis and seborrheic dermatitis, and delivering consistent revenue growth.

“Todd is an exceptional commercial leader whose deep experience building and launching immunology and dermatology franchises makes him an ideal fit as we advance ORKA-001 and ORKA-002 toward commercialization,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Todd’s appointment reflects our commitment to building a world-class organization prepared to deliver differentiated medicines to patients with chronic skin diseases.”

Prior to Arcutis, Mr. Edwards served as Group Vice President, Business Head, Immunology at Incyte Corporation, where he built a new dermatology business unit and launched two first-in-class dermatology therapies. Earlier, he held roles of increasing scope at UCB S.A. as Senior Vice President, leading U.S. Immunology and, subsequently, Global Immunology Operations and Strategy. At UCB he meaningfully scaled U.S. immunology net sales across dermatology, rheumatology, and gastroenterology and led global portfolio strategy across the company’s biologics franchises in psoriatic and related inflammatory diseases. Earlier in his career, Mr. Edwards held senior roles at AbbVie and TAP Pharmaceuticals. He is a decorated veteran of the U.S. Army. Mr. Edwards received a B.S. from East Tennessee State University and an M.B.A. from Embry-Riddle Aeronautical University. 

“I’m thrilled to join Oruka at such a pivotal moment,” said Mr. Edwards. “Oruka’s portfolio of potentially best-in-class biologics has the opportunity to redefine what patients with psoriatic disease and other chronic skin diseases can expect from treatment. I look forward to helping build the commercial foundation to bring these differentiated medicines to patients.”

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.

Forward Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Oruka’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, the potential benefits, efficacy, safety, durability of response, dosing profile and therapeutic potential of ORKA-001 and ORKA-002; and Oruka’s plans and ability to build, scale and execute its commercial organization and capabilities and ultimately bring its product candidates to patients. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements except as required by applicable law.

Investor Contact:

Alan Lada
(650)-606-7911
[email protected]

BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) — Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced two upcoming poster presentations at the European Respiratory Society (ERS) International Congress 2026, being held September 5-9, 2026, in Barcelona, Spain.

ERS 2026 Poster Presentation Details:

Poster Title: Understanding patient perspectives on IPF clinical trial participation: Preferences, motivations, and comfort with study design
Poster Session: #246: Real-world studies: acute exacerbations and pulmonary fibrosis treatment
Presenting Author: Brittany Davis, Ph.D., Avalyn Pharma
Location: PS-34, Poster #: PA3014
Date and Time: September 7, 2026, between 8:00 a.m. – 9:30 a.m. GMT (4:00 a.m. – 5:30 a.m. EDT)

Poster Title: In silico modeling of a novel nebulized pirfenidone formulation (AP01) predicts aerosol distribution throughout the lung
Poster Session: #378: Molecular mechanisms and clinical strategies in interstitial lung diseases
Author: Michelle Palacios, Ph.D., DABT, Avalyn Pharma
Session: PS-9, Poster #: PA4377
Date and Time: September 7, 2026, between 12:30 p.m. – 2:00 p.m. GMT (8:30 a.m. – 10:00 a.m. EDT)

See the ERS online program for more details. The presentations will also be accessible on the company’s website.

About Avalyn Pharma

Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.

Investor Contact:

Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
[email protected]

Media Contact:

Precision AQ
[email protected]

SPRINGDALE, Ark., Aug. 24, 2026 (GLOBE NEWSWIRE) — Today, Tyson Foods announced a $1 million commitment over the next two years in support of the Harvest to Hallways initiative, advancing efforts to improve childhood nutrition and food access.

Funding from the commitment will help expand student access to healthy school meals, support nutrition education and strengthen meal access in rural communities.

Tyson Foods will leverage its existing partnerships with GENYOUth, Boys & Girls Clubs of America and the Food Research & Action Center (FRAC) to help deliver these programs in schools and communities across the country.

“At Tyson Foods, our purpose is to feed the world like family, and that starts with helping children access the nutrition they need to reach their full potential,” said Donnie King, President & CEO of Tyson Foods. “We’re proud to support the Harvest to Hallways initiative and work alongside organizations that are making a meaningful difference for students and families across the country.”

The Harvest to Hallways initiative brings together public and private sector partners to support healthier school meals, nutrition education and improved food access for children nationwide.

Tyson Foods’ $1 million commitment will be distributed over two years through its nonprofit partners, with programs focused on:

• Expanding access to healthy school meals through innovative school nutrition solutions
• Supporting nutrition education and resources for schools
• Increasing meal access for children in rural communities

For more information about Tyson Foods’ community impact and food access initiatives, visit TysonFoods.com.

About Tyson Foods, Inc.

Tyson Foods, Inc. (NYSE: TSN) is a world-class food company and recognized leader in protein. Founded in 1935 by John W. Tyson, it has grown under four generations of family leadership. The Company is unified by this purpose: Tyson Foods. We Feed the World Like Family™ and has a broad portfolio of iconic products and brands including Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, State Fair®, Aidells® and ibp®. Tyson Foods is dedicated to bringing high-quality food to every table in the world, safely and affordably, now and for future generations. Headquartered in Springdale, Arkansas, the Company is a member of the S&P 500 and Russell 1000 large capitalization indices. It had approximately 133,000 team members on September 27, 2025. Visit www.tysonfoods.com.

[email protected]

Orlando, FL, Aug. 24, 2026 (GLOBE NEWSWIRE) —
Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented reality diving technology (“DAVD”), will host a conference call on Monday, September 14, 2026 at 10:00 a.m. Eastern time to discuss its financial results for the fiscal third quarter ended July 31, 2026. A press release detailing these results will be issued before the opening of trading on September 14, 2026.

The Company’s management will provide prepared remarks, followed by a question-and-answer period.

Date: Monday, September 14, 2026
Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)
U.S. dial-in numbers: 1-877-451-6152 or 1-201-389-0879
International number: 1-201-389-0879
Conference ID: 13762021

The conference call will broadcast live and be available for replay here.

Persons interested in attending are required to call the conference telephone number approximately 10 minutes before the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please press *0.

A replay of the call will be available after approximately 2:00 p.m. Eastern time on the same day through Monday, September 28, 2026 at 11:59 p.m. ET.

Telephone replay numbers: 1-844-512-2921 or 1-412-317-6671
International replay number: 1-412-317-6671
Access ID: 13762021

About Coda Octopus Group, Inc.

The Company, founded in 1994, is an established supplier to the underwater and subsea market. The Company supplies a range of proprietary hardware and software solutions, including its market-leading real-time 4D/5D/6D imaging sonar technologies, marketed under the names Echoscope^®, Echoscope PIPE^® and Echoscope PIPE NANO Gen Series^®, as well as its next-generation diving technology, the Diver Augmented Vision Display (“DAVD”) system.

The Company’s Echoscope PIPE^® sonar technology generates real-time 3D/4D/5D imagery of moving objects underwater, including in zero-visibility conditions. Echoscope technology is used globally across numerous commercial offshore and defense subsea applications.

Applications for Echoscope^® technology include subsea mapping, intervention and asset placement; salvage and recovery; search and rescue; offshore renewable energy projects, including cable installation and surveys; marine construction; subsea infrastructure installation; mining; robotics and 3D perception; breakwater construction and monitoring; decommissioning; diving operations; and port and harbor security.

The Company’s recently launched DAVD technology is designed to enhance commercial and defense diving operations by providing a fully integrated system that connects topside personnel and divers. The system enables both parties to visualize the same underwater scene and exchange critical information in real time. DAVD also integrates the Company’s sonar technology, enabling dive operations to be conducted in zero-visibility conditions, a common challenge in underwater environments.

The Company also includes two discrete Defense Engineering Services businesses, Coda Octopus Martech Ltd (UK-based) and Coda Octopus Engineering, Inc. (US-based), which principally supply mission-critical sub-assemblies as subcontractors to major defense prime contractors. Their scope of supply typically includes concept development, design, prototyping, manufacturing and post-sale support. This business model provides the potential for repeat orders throughout the life cycle of the underlying defense programs.

The Company recently acquired Precision Acoustics Limited (“PAL”), an acoustic sensors and materials business. PAL supplies acoustic sensors and materials and performs calibration services for medical devices. PAL is accredited to the ISO/IEC 17025 standard and is one of a limited number of organizations in the United Kingdom accredited to perform these specialized measurements. Globally, only a small number of facilities hold ISO/IEC 17025 accreditation for these measurements.

Ultrasonic free-field sensitivity calibration is critical for markets that require precision ultrasonic measurement, strict safety compliance and full metrological traceability. These include regulated and high-risk applications such as diagnostic and therapeutic medical ultrasound, defense and underwater acoustics, where free-field calibration is essential to ensure accurate beam sensitivity and minimize interference. PAL’s operations are based in the United Kingdom.

For further information, please visit Coda Octopus Group or contact us at [email protected].

Forward Looking Statements

This press release contains forward-looking statements concerning Coda Octopus Group, Inc. within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect”, “assume” and similar expressions are intended to identify forward‐looking statements. Those forward-looking statements include, without limitation, statements regarding the Company’s expectations for the growth of the Company’s operations and revenue. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, fluctuations in foreign exchange rates, changes in global economic conditions, tariff and trade policies, reductions in defense spending, changes in customer demand, geopolitical developments, the outcome of our ongoing research and development efforts relating to our products, including our patented real-time 3D solutions and DAVD technology, our ability to expand our sales and marketing capabilities, and the other risk factors described in our Annual Report on Form 10-K for the year ended October 31, 2025, filed with the Securities and Exchange Commission on January 29, 2026, as amended by Form 10-K/A filed on February 26, 2026.

Coda Octopus Group, Inc., does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact:

Mr. Dillon King
Investor Relations
Coda Octopus Group, Inc.
Email: [email protected]
Tel: +1-407-735-2406

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a Virtual Commercial Day on Wednesday, September 2, 2026, from 8:00 – 9:30 a.m. ET.

Belite Bio’s management team will be joined by leading experts in ophthalmology and people living with Stargardt disease type 1 (STGD1), and will provide an overview of STGD1, the unmet need of people living with the disease, and the current treatment landscape. Management will also provide an update on the Company’s prelaunch preparedness strategies and the potential commercial opportunity for tinlarebant in STGD1, if approved by the U.S. Food and Drug Administration (FDA).

In August 2026, the FDA accepted and granted Priority Review designation of the New Drug Application for tinlarebant for the treatment of STGD1. The FDA has set a Prescription Drug User Fee Act date of February 12, 2027.

Webcast Information

Date: Wednesday, September 2, 2026
Time: 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)
Webcast Link: https://events.q4inc.com/attendee/785241581

Webcast Link Instructions

A webcast of the event can be accessed and a replay will be archived under “Events” in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.

About Belite Bio

Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:

[email protected]

New York, NY, Aug. 24, 2026 (GLOBE NEWSWIRE) —  Alpha Compute Corp. (NASDAQ: ALP) (“Alpha Compute” or the “Company”), a high-performance GPU infrastructure and confidential-compute technology company serving the artificial intelligence economy, today announced additional appointments to its Global Infrastructure Business.

The appointments are designed to enhance the technical execution and client support team behind a rapidly growing Global Infrastructure sales pipeline.

Anne Schoofs has been appointed Vice President, Client Success, Global Infrastructure Business, where she will lead the charge in managing our strategic enterprise accounts, ensuring that our clients’ high-density compute and AI infrastructure deployments operate at peak efficiency. Her leadership will be instrumental in driving seamless technical onboarding, optimizing workload performance, and building enduring partnerships as we expand our global data center capabilities.

Jose Rios joins as Advisor, Global Infrastructure Business, providing counsel on silicon strategy, high-density compute architecture, and data center design as the Company scales its Blackwell-class fleet.

“As demand for high-density, AI-ready compute accelerates, our ability to deliver is about the people who make sure every deployment performs flawlessly from day one,” said Brittany Kaiser, CEO of Alpha Compute. “Anne’s track record turning enterprise relationships into long-term partnerships, paired with Jose’s deep silicon and data center expertise, gives us exactly the execution muscle we need to scale responsibly against a $1.5 billion pipeline. We’re building the infrastructure backbone of the AI economy, and that requires the best operational talent in the industry, which is exactly what these appointments bring to Alpha Compute.”

About the Appointees

Anne Schoofs — Vice President, Client Success, Global Infrastructure Business

Schoofs brings over two decades of Fortune 500 client account management with deep expertise in enterprise relationship management and technical onboarding at Sprint, Wipro, ATOS/Maven, and SymphonyAI.  She holds a bachelor of arts with honors from Harvard University where she was a member of their varsity women’s golf team.  She also studied data science at Johns Hopkins University. LinkedIn:linkedin.com/in/anneschoofs

Jose Rios — Advisor, Global Infrastructure Business

Rios is the former Vice President and General Manager of Custom Solutions (Data Center and AI) at Intel, with roughly 25 years in compute infrastructure and silicon. At Intel, he led data center programs and custom silicon efforts spanning gaming, and autonomous driving. LinkedIn:linkedin.com/in/siliconjose

About Alpha Compute Corp. 
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute. Alpha Compute’s mission is to support clients, subsidiaries, and partners across critical sectors including: finance, defense, intelligence, and media with the essential framework for any organization requiring secure, confidential computing environments. For more information, please visit: https://www.alphacompute.ai/ 

Alpha Compute Corp is domiciled in the British Virgin Islands with offices in New York, Los Angeles, Miami, Amsterdam and Toronto. Alpha Compute is a founding partner of the Right2Compute Coalition; more information is available at www.right2compute.com 

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements. 

These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: the timing and progress of the Company’s strategic initiatives; reliance on third-party vendors and partners; the ability to secure additional financing; uncertainty around the Company’s investments and legacy business; risks related to technology platforms and ecosystems; and general market and economic conditions. A more complete discussion of these risks is set forth under “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2026. 

Undue reliance should not be placed on these forward-looking statements. The forward-looking statements contained herein are made as of the date of this press release, and the Company undertakes no obligation to update or revise them publicly, except as required by law. 

Investor & Media Contact 
Alpha Compute Corp. 
[email protected] 
www.alphacompute.ai 

ir(at)alphacompute.ai 

CHICAGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced it is projecting Oliv18™ to generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months, representing approximately $4.3 million in gross profit at an expected gross margin of approximately 72%.

Oliv18™ is part of the Company’s “18 Series,” a growing portfolio of science-based nutraceutical products. It is a whole olive polyphenol formulation, USDA and EU organic certified and produced through a 100% solvent-free process, entering the U.S. market across the cardiovascular health and antioxidant categories.

The Company’s projection is underpinned by a staged rollout beginning with direct-to-consumer e-commerce, with planned expansion into selected retail channels over time. The forecast incorporates internal assumptions around pricing, anticipated sales volumes, repeat purchase behavior, and distribution growth, and remains subject to the continued execution of the Company’s commercialization plans.

According to Grand View Research, the U.S. cardiovascular health supplements market was estimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by 2030. The U.S. antioxidants market was valued at $1.66 billion in 2025 and is projected to nearly double to $3.18 billion by 2035, according to Precedence Research.

Greg Siokas, CEO of Cosmos Health, stated: “Oliv18™ extends our 18 Series into two established categories in consumer wellness, where demand continues to shift toward products supported by scientific substantiation. We believe it has the potential to become a meaningful revenue contributor to our nutraceutical portfolio as we scale distribution.”

About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications
[email protected]

BIRMINGHAM, Ala., Aug. 24, 2026 (GLOBE NEWSWIRE) — ServisFirst Bank, a subsidiary of ServisFirst Bancshares (NYSE:SFBS), is pleased to announce they have ranked sixth in the top-performing United States banks with between $10 billion to $50 billion in assets, according to American Banker’s annual list. The banks are ranked by the consulting firm Capital Performance Group based on their three-year average return on average equity, or ROAE, using data from year-end 2025. Previously, ServisFirst Bancshares, Inc. was ranked fifth based on year-end 2024 data.

“Being recognized among the country’s top-performing banks is a meaningful reflection of the consistency and commitment of our entire team,” states Tom Broughton, ServisFirst Bank Chairman, President, and CEO. “Our performance is rooted in staying focused on our customers, making thoughtful decisions and maintaining the high standards we have set for ourselves since the Bank was founded. We are proud of what our team has accomplished and grateful for the trust our customers and shareholders continue to place in us. We remain focused on carrying that momentum forward as we grow and serve our markets.”

ServisFirst Bancshares, Inc., an $18 billion-asset institution, reported a three-year average ROAE of 15.39% and reported a 2025 net interest margin of 3.12%.

In the American Bankerarticle, Claude Hanley, founder and partner at Capital Performance Group, said one of the biggest differences between the top-performing banks and the broader group was funding. The top 10 held a larger share of low-cost demand deposits, such as checking and money market accounts, giving them a cheaper source of funding for loans and helping preserve margins even as interest rates declined. Hanley also said there was no huge turnover among the top 10 performers, adding that the banks included in the ranking “outperformed in almost every aspect.”

As the only Alabama-based institution to rank in the top ten, ServisFirst Bank continues to strengthen its reputation as a high-performing, well-capitalized financial institution. This recognition underscores the Bank’s ability to deliver strong financial results in a competitive market, reinforcing its role as a trusted partner for businesses and individuals across the Southeast.

For more information regarding ServisFirst Bank’s recent American Banker ranking, please contact Krista Conlin at [email protected]. For more about ServisFirst Bank, please visit www.servisfirstbank.com.

ABOUT SERVISFIRST BANK

ServisFirst Bank is a full-service commercial bank focused on commercial banking, correspondent banking, treasury management, private banking and the professional consumer market, emphasizing competitive products, state-of-the-art technology and a focus on quality service. Recently, the Bank announced that its assets exceed $18 billion. The Bank offers sophisticated treasury management products, Internet banking, home mortgage lending, remote deposit express banking, and highly competitive rates. 

ServisFirst Bank was formed in May 2005, and has offices in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, Texas, and Virginia. In April 2015, and annually thereafter, ServisFirst Bank has earned investment- grade ratings and a stable outlook from Kroll Bond Rating Agency (KBRA), which measures companies’ financial fundamentals. ServisFirst Bancshares, Inc. files periodic reports with the U.S. Securities and Exchange Commission (SEC). Copies of its filings may be obtained at www.servisfirstbancshares.com.

FOR INFORMATION CONTACT

Krista Conlin, [email protected]

NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) — Wolf Haldenstein Adler Freeman & Herz LLP, a nationally recognized securities litigation law firm, reminds investors that a securities fraud class action lawsuit has been filed against Microvast Holdings, Inc. (NASDAQ : MVST) (“Microvast” or the “Company”), on behalf of those who purchased or acquired Microvast common stock between April 1, 2025 and March 16, 2026, inclusive.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Investors who purchased Microvast shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for September 21, 2026.

The filed complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:

• due to, inter alia, inventory management issues and delays in commercial vehicle rollouts by Microvast’s customers, Defendants had overstated Microvast’s ability to reach its margin targets;
• Defendants overstated Microvast’s ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and
• as a result, Defendants’ public statements were materially false and misleading at all relevant times.

The market received its first hint of the true state of Microvast’s business and operations on June 25, 2025, when the short seller, Grizzly Research, issued a report concerning Microvast (the “Grizzly Report”), alleging that the Company “is fabricating a significant part of its business and capabilities”, including, inter alia, by overstating the level of activity at its production facilities, including the Huzhou facility, and likewise overstating the prospective economic opportunities from its commercial partnerships.

Following publication of the Grizzly Report, Microvast’s stock price plunged during intraday trading, falling as much as $0.40 per share, or approximately 10.23%, before ultimately closing at $3.90 per share. Then, barely one month after the Grizzly Report, on August 1, 2025, Microvast announced the departure of its Chief Financial Officer, Charles Schultz, just three months after he joined the Company. On this news, Microvast’s stock price fell $0.30 per share, or approximately 9.93%, to close at $2.72 per share on August 4, 2025.

Subsequently, operating results for the quarter ended September 30, 2025, in which it revealed that production following the Huzhou Phase 3.2 expansion would not begin until Q1 2026 – after repeatedly advising investors that the additional capacity associated with the expansion would be online by Q4 2025. On this news, Microvast’s stock price fell $0.50 per share, or approximately 10%, to close at $4.48 per share on November 11, 2025.

Finally, on March 16, 2026, Microvast issued a press release reporting its financial and operating results for the quarter and year ended December 31, 2025. Among other items, Microvast reported that gross margin declined to approximately 1% for the quarter, down sharply from approximately 36% for the same period in the prior year, which the Company attributed to inventory impairment charges arising from “specialized ESS components”. Microvast also reported revenue of $96.5 million for the quarter, representing a 15% year-over-year decrease and falling well short of the consensus estimate of $136.4 million. Microvast attributed this result to “regulatory shifts in South Korea and delays in customer platform ramp-up” in Europe, the Middle East, and Africa.

On this news, Microvast’s stock price fell $0.79 per share, or 34.2%, to close at $1.52 per share on March 17, 2026.

WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

• Phone: (800) 575-0735 or (212) 545-4774
• Email: 
  [email protected]
• Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.